期刊文献+

SNCG基因转染对PC-3细胞抗肿瘤药物作用效果的影响 被引量:2

Influence of SNCG Transfection on the Effectiveness of Anti-tumor Drugs in PC-3 Cell Lines
下载PDF
导出
摘要 目的:观察转染了质粒PCI-NEO-SNCG后的前列腺癌激素非依赖性细胞系PC-3细胞对抗肿瘤药物顺铂(DDP)、5-氟尿嘧啶(5-FU)、阿霉素(ADM)、长春新碱(VCR)、紫杉醇(TAX)的敏感性,探讨SNCG的表达对各种抗肿瘤药物作用效果的影响。方法:转染质粒PCI-NEO和PCI-NEO-SNCG至PC-3细胞,采用RT-PCR法检测PC-3细胞中SNCG的表达;MTT法检测各抗肿瘤药物对转染后PC-3细胞的抑制作用;流式细胞术分析转染细胞经TAX作用后的细胞周期及凋亡。结果:5种抗肿瘤药物对转染了空载体PCI-NEO质粒及PCI-NEO-SNCG质粒细胞的生长抑制作用均存在时间依赖性;转染PCI-NEO的PC-3细胞组与转染PCI-NEO-SNCG的PC-3细胞组中各种抗肿瘤药物的抑制效果比较显示,DDP、5-FU、ADM、VCR的抑制效果两组间没有显著性差异(P>0.05),而TAX对转染PCI-NEO-SNCG的细胞的抑制率较转染PCI-NEO的细胞显著降低(P<0.01);经TAX处理48 h后,在转染PCI-NEO质粒的细胞中,停留在G2-M期的细胞比例显著高于转染PCI-NEO-SNCG质粒的细胞(P<0.01),而停留在G0-G1期及S期的细胞比例,在转染PCI-NEO质粒的细胞中显著低于转染PCI-NEO-SNCG质粒的细胞(P<0.01);在转染PCI-NEO质粒的细胞中Caspase-3的表达显著高于转染PCI-NEO-SNCG质粒的细胞(P<0.01)。结论:TAX对转染了SNCG基因的PC-3细胞中的生长抑制作用明显降低,提示SNCG的表达可抑制TAX的作用效果,这一发现可为前列腺癌的个体化治疗提供理论依据和指导。 Objective: To observe the sensitivity of the PC-3 cell lines transfected with the PCI-NEO-SNCG plasmid to Cisplatin ( DDP), 5-Fluorouraeil (5-FU), Adriamyein (ADM), Vinefistine (VCR) and Paclitaxel ( TAX), and to explore the influence of the SNCG expression on the effectiveness of anti-tumor drugs. Methods: The plasmids PCI-NEO and PCI-NEO-SNCG were transfected into the hormone-independent prostate cancer cell lines PC-3. RT-PCR was adopted to examine the expression of SNCG in the PC-3 cell lines. The MTr method was employed to detect the suppressive effects of different anti-tumor drugs ( DDP, ADM, 5-FU, VCR and TAX) on the cell lines transfected with PCI-NEO and PCI-NEO-SNCG. Flow cytometry was used to analyze the cell cycles and apoptosis of the transfected cells treated with TAX. Results : The 5 anti-tumor drugs suppressed the growth of the cell lines transfected with the plasmids PCI-NEO and PCI-NEO-SNCG in a time-dependant manner. The comparison between the growth-suppressing effects of different anti-tumor drugs on the PC-3 cell lines showed no significant differences between the group transfected with PCI-NEO and that with PCI-NEO-SNCG in DDP, 5-FU, ADM and VCR (P 〉 0.05), while the rate of suppression of TAX on the latter cell lines was significantly lower than that on the former (P 〈 0.01 ). Compared with the PCI-NEO-SNCG plasmid transfected cell lines, after treated with TAX for 48 hours, those transfected with the PCI-NEO plasmid exhibited a significantly larger proportion of cells remaining in the G2-M stage (P 〈 0.01 ), a smaller proportion in the G0-G1 and S stages (P 〈 0.01 ) and a significantly higher expression of Caspase- 3 (P 〈 0. 01 ). Conclusion: The significant reduction of the growth-suppressing effect of TAX in the SNCG-transfected PC-3 cell lines suggests that the expression of SNCG may restrain the effect of TAX. These findings have provided evidence and guide to the individual chemotherapy of prostate cancer.
出处 《中华男科学杂志》 CAS CSCD 2008年第12期1077-1082,共6页 National Journal of Andrology
基金 南京市科技局科技发展指导性计划基金(2005指导0584)
关键词 SNCG基因 前列腺癌 PC-3细胞 转染 紫杉醇 SNCG gene prostate cancer PC-3 cell transfection Paclitaxel
  • 相关文献

参考文献14

  • 1Fizazi K,Martinez LA,Sikes CR,et al.The association of p21^(WAF-1/CIPI) with progression to androgen-independent prostate cancer [ J ]. Clin Cancer Res, 2002, 8(3) : 775-781. 被引量:1
  • 2Mathew P, Dipaola R. Taxane refractory prostate cancer[ J]. J Urol, 2007, 178(3 Pt2): S36-S41. 被引量:1
  • 3Zhou Y, Inaba S, Liu J. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment[J]. Int J Oncol, 2006, 29(1 ) : 289-295. 被引量:1
  • 4Singh VK, Zhou Y, Marsh JA. et al. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs [ J ]. Cancer Res, 2007, 67 ( 2 ) : 626-633. 被引量:1
  • 5Sondak VK, Bertelsen CA, Kern DH, et al. Evolution and clinical application of a rapid chemosensitivity assay [ J ]. Cancer, 1985, 55(6) : 1367-1371. 被引量:1
  • 6Huber M, Bahr I, Kratzschmar JR, et al. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r [ J ]. Mol Cell Proteomics, 2004, 3 (1): 43-55. 被引量:1
  • 7何帮顺,潘玉琴,瞿卫,立彦,王自正,王书奎.化疗药物对高表达SNCG的乳腺癌细胞株T47D的抑制作用的实验研究[J].南京医科大学学报(自然科学版),2007,27(8):821-824. 被引量:3
  • 8Lavedan C. The synuclein family[J]. Genome Res, 1998, 8 (9) : 871-880. 被引量:1
  • 9Liu H, Liu W, Wu Y, et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers [ J ]. Cancer Res, 2005, 65 ( 17 ) : 7635- 7643. 被引量:1
  • 10Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-ramma enhanced cancer cell motility [J]. Int J Oncol, 2006, 29(5) : 1201-1205. 被引量:1

二级参考文献77

  • 1孙明,杨宇如,李虹,陈一戎,王志平,卢一平,魏强,岳中瑾.紫杉醇和吉西他滨对前列腺癌PC-3细胞的作用[J].中华男科学杂志,2004,10(9):658-661. 被引量:4
  • 2孙明,李虹,杨宇如,魏强,卢一平,李响,李杜渐.多西紫杉醇和维甲酸对前列腺癌PC-3细胞的协同作用[J].四川大学学报(医学版),2004,35(6):797-801. 被引量:5
  • 3张世革,王益华,丁毅,吴烨.晚期前列腺癌联合雄激素阻断治疗的长期随访[J].中华男科学杂志,2005,11(10):770-771. 被引量:2
  • 4Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostare cancer[J]. N Engl J Med, 2004, 351(15) :1488-1490. 被引量:1
  • 5Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer[ J ].Eur Urol, 2001, 39(2) :121-130. 被引量:1
  • 6Chen CD, Welsbie D, Tran C, et al. Molecular determinants of resistance to antiandregen therapy[J]. Nat Med, 2004, 10( 1 ) :33-39. 被引量:1
  • 7Hasumi H, Ishiguro H, Nakamura M, et al. Neuroserpin (PI-12 ) is upregulated in high-grade prostate cancer and is associated with survival[J]. Int J Cancer, 2005, 115(6) : 911-916. 被引量:1
  • 8Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractary disease [ J ]. Endocr Relat Cancer, 2005, 12(1): 109-117. 被引量:1
  • 9Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004, 351( 15 ) : 1513-1520. 被引量:1
  • 10Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15) :1502-1512. 被引量:1

共引文献26

同被引文献4

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部